Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Velos continues adding CTSA customers - 40% now use Velos products



FREMONT, Calif., June 30, 2015 /PRNewswire/ -- Velos, Inc., the pioneering software company for clinical research and specialty medicine, continues to grow and add customers who receive Clinical and Translational Science Awards ("CTSAs").  More than 40% of the 62 CTSAs awarded by the National Institutes of Health currently use Velos software for clinical research information management. This is among the largest such market shares in its product class. 

"Our presence in the CTSA community keeps growing as a result of our continued intense focus on the particular challenges and needs of this very important group of clinical researchers," says John S. McIlwain, President of Velos.

As clinical studies continue to increase in complexity, it is more challenging than ever to ensure that efficiency and compliance are being addressed and that patients are being treated in the most ethical manner possible. Velos helps research organizations address these issues through an integrated platform that enables management of the entire clinical research portfolio across multiple departments and sites, while also establishing a powerful foundation designed with industry standards, scalability and interoperability in mind. The return on investment is vast and varied, including faster study setup and turnaround time, improved accrual, increased regulatory compliance, more accurate and comprehensive research billing, reduced staff workloads, and higher data quality. Velos' solutions provide the CTSA community with a platform that creates an efficient and connected ecosystem and promotes administrative and scientific excellence while ensuring a strong, scalable and adaptable solution for their evolving needs.

Velos expects continued growth in the CTSA community through its flagship Velos eResearch product as well as Velos eResearch sister products for clinical research and translational medicine.  What's more, over the last several years the company has made major R&D investments to further extend the value and utility of its core clinical research product line. These innovations are scheduled to hit the market later in 2015 and beyond.

About Velos:

Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the world. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. Velos integrates the clinical, administrative and financial information needs of research management, with an emphasis on flexibility and workflow and empowering clinical innovation. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California.

 

SOURCE Velos, Inc.


These press releases may also interest you

at 20:03
Bombardier is pleased to announce that it has reached collective bargaining agreements with the more than 2,100 production and office workers, represented by Unifor Locals 112 and 673, at its site in...

at 20:00
China is stepping into a new phase in this new age, is deeply implementing innovation-driven strategy, is speeding up building of an innovative state and is continuously promoting "Mass Entrepreneurship and Innovation" to a new level. On Jun 22,...

at 19:55
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed, a global biopharmaceutical company developing...

at 17:00
Open Access publishing is gaining popularity as the world is increasingly connected online today, facilitating archiving, indexing, data mining, retrieving, and speedy distribution of researched information. Open access publishing is producing a...

at 17:00
A new global study from SMART Technologies, the world leader in education technology, gives insight into how a school's approach to planning, implementing and using technology can impact teaching and learning outcomes. Released today, the study...

at 17:00
Renovatm Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...




News published on 30 june 2015 at 18:26 and distributed by: